24/7 Wall Street
02 Jul 2026, 13:33 UTC · 19w ago
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
Impact · against what's priced in
Voyager Therapeutics faces a stark conflict between high analyst targets and deteriorating fundamentals, including a massive revenue miss and high dilution risk. While the upcoming 2026 Alzheimer's trial dosing is a potential catalyst, the immediate operational instability from the CFO resignation and share authorization offsets the speculative upside.
- OCGN+0.30
No priced-in read yet





